Details of the Drug Combination

General Information of Drug Combination (ID: DC4EIYJ)

Drug Combination Name
Prasugrel Bivalirudin
Indication
Disease Entry Status REF
Myocardial Infarction Phase 1 [1]
Component Drugs Prasugrel   DM7MT6E Bivalirudin   DMECRX1
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Prasugrel
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [2]
Prasugrel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
P2Y purinoceptor 12 (P2RY12) TTZ1DT0 P2Y12_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Prasugrel Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [5]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [5]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [5]
------------------------------------------------------------------------------------
Indication(s) of Bivalirudin
Disease Entry ICD 11 Status REF
Thrombocytopenia 3B64 Approved [3]
Bivalirudin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Coagulation factor IIa (F2) TT6L509 THRB_HUMAN Inhibitor [6]
Trypanosoma Trypanothione reductase (Trypano TPR) TTRTKPV TYTR_TRYBB Inhibitor [7]
------------------------------------------------------------------------------------
Bivalirudin Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Decreases Expression [8]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [9]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Decreases Activity [10]
Proteinase-activated receptor 4 (F2RL3) OTUNAKDB PAR4_HUMAN Decreases Activity [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00976092) Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7562).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6470).
4 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5 The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
6 New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
7 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8.
8 Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31.
9 The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis. 2005 Sep;16(6):401-5. doi: 10.1097/00019501-200509000-00010.
10 Bivalirudin: a new promising direct antithrombin. Indian Heart J. 2007 May-Jun;59(3):288-94.